# VIEW 2q8 Protocol - Aflibercept Fixed Dosing (Improved Parameters)
# Based on VIEW 1/2 trials: 3 monthly loading doses then every 8 weeks
# Calibrated to achieve target outcomes: +8.4 letters at Year 1, ~31% gaining ≥15 letters

name: "VIEW 2q8 Fixed Dosing - Improved"
version: "2.0"
created_date: "2025-01-26"
author: "Calibration Team"
description: "Fixed dosing protocol based on VIEW trials with improved parameters to match clinical outcomes"

# Protocol type - fixed dosing, not treat-and-extend
protocol_type: "fixed_interval"
min_interval_days: 56  # 8 weeks for maintenance
max_interval_days: 56  # Fixed interval, no extension
extension_days: 0      # No extension in fixed protocol
shortening_days: 0     # No shortening in fixed protocol

# Special parameters for VIEW 2q8
loading_phase:
  enabled: true
  doses: 3
  interval_days: 28  # Monthly during loading (weeks 0, 4, 8)

# Disease state transitions - calibrated to achieve VIEW outcomes
# More optimistic than standard protocols to match trial results
disease_transitions:
  NAIVE:
    NAIVE: 0.0        # Cannot remain naive after first assessment
    STABLE: 0.55      # 55% achieve stability quickly (increased from 45%)
    ACTIVE: 0.40      # 40% have active disease (decreased from 45%)
    HIGHLY_ACTIVE: 0.05  # 5% have severe disease (decreased from 10%)
  STABLE:
    NAIVE: 0.0        # Cannot return to naive
    STABLE: 0.90      # 90% remain stable (high retention)
    ACTIVE: 0.10      # 10% develop recurrence
    HIGHLY_ACTIVE: 0.0  # Rare to jump directly to highly active
  ACTIVE:
    NAIVE: 0.0        # Cannot return to naive
    STABLE: 0.45      # 45% achieve stability with treatment (increased from 35%)
    ACTIVE: 0.50      # 50% remain active (decreased from 60%)
    HIGHLY_ACTIVE: 0.05  # 5% progress to highly active (unchanged)
  HIGHLY_ACTIVE:
    NAIVE: 0.0        # Cannot return to naive
    STABLE: 0.10      # 10% achieve stability
    ACTIVE: 0.30      # 30% improve to active
    HIGHLY_ACTIVE: 0.60  # 60% remain highly active

# Treatment effect on disease transitions
# Stronger effect to match VIEW outcomes
treatment_effect_on_transitions:
  NAIVE:
    multipliers: {}
  STABLE:
    # Treatment strongly maintains stability
    multipliers:
      STABLE: 1.2     # 20% more likely to stay stable
      ACTIVE: 0.8     # 20% less likely to become active
  ACTIVE:
    # Treatment strongly promotes improvement
    multipliers:
      STABLE: 3.0     # 3x more likely to become stable (increased from 2.5x)
      ACTIVE: 0.6     # 40% less likely to stay active (decreased from 0.7)
      HIGHLY_ACTIVE: 0.2  # 80% less likely to worsen (decreased from 0.3)
  HIGHLY_ACTIVE:
    # Treatment effect present but limited
    multipliers:
      STABLE: 2.0     # Twice as likely to improve dramatically
      ACTIVE: 1.8     # 80% more likely to improve
      HIGHLY_ACTIVE: 0.6  # 40% less likely to remain severe

# Vision change model - calibrated to achieve +8.4 letters mean at Week 52
vision_change_model:
  # During loading phase and maintenance, vision improves more aggressively
  naive_treated:
    mean: 4.5    # Strong initial response (increased from 3)
    std: 2
  naive_untreated:
    mean: -3   # Untreated naive patients lose vision
    std: 2
  stable_treated:
    mean: 2.5  # Continued improvement when stable (increased from 1.5)
    std: 1.5
  stable_untreated:
    mean: -0.5  # Slight decline without treatment
    std: 1
  active_treated:
    mean: 1.5   # Moderate improvement even when active (increased from 0.5)
    std: 2
  active_untreated:
    mean: -3    # Significant loss without treatment
    std: 2
  highly_active_treated:
    mean: 0.5  # Slight improvement with treatment (changed from -0.5)
    std: 2
  highly_active_untreated:
    mean: -5    # Severe loss without treatment
    std: 3

# Baseline vision distribution based on VIEW trials
baseline_vision_distribution:
  type: normal
  mean: 53.7      # Average of VIEW 1 (55.7) and VIEW 2 (51.6)
  std: 13.4       # Average of VIEW 1 (12.8) and VIEW 2 (13.9)
  min: 20         # Protocol minimum
  max: 85         # Protocol maximum

# Discontinuation rules - very low in clinical trials
discontinuation_rules:
  # Poor vision criteria
  poor_vision_threshold: 20        # Very low threshold
  poor_vision_probability: 0.02    # 2% chance per visit when below threshold
  
  # High injection burden criteria - not applicable for fixed protocol
  high_injection_count: 999        # Effectively disabled
  high_injection_probability: 0.0  # No burden-based discontinuation
  
  # Long treatment duration criteria - minimal in trials
  long_treatment_months: 24        # 2 years
  long_treatment_probability: 0.005 # 0.5% chance per visit after duration
  
  # Types of discontinuation
  discontinuation_types:
    - "planned"      # Patient/doctor decision
    - "adverse"      # Due to adverse events
    - "ineffective"  # Treatment not working

# Clinical improvements for enhanced realism
clinical_improvements:
  enabled: true
  use_loading_phase: true
  use_time_based_discontinuation: false  # Use protocol discontinuation rules
  use_response_based_vision: true
  use_baseline_distribution: false  # Use protocol distribution
  use_response_heterogeneity: true
  
  # Response types calibrated to match VIEW outcomes
  response_types:
    good:
      probability: 0.31    # ~31% gain ≥15 letters
      multiplier: 2.5      # Strong response (increased from 2.0)
    average:
      probability: 0.64    # ~64% gain 0-14 letters  
      multiplier: 1.5      # Moderate response (increased from 1.2)
    poor:
      probability: 0.05    # ~5% lose vision (100% - 95% maintenance rate)
      multiplier: 0.5      # Poor response (increased from 0.3)
  
  # Vision response parameters for different phases
  vision_response_params:
    loading:
      mean: 5.0    # Strong improvement during loading (increased from 3.5)
      std: 1.5
    year1:
      mean: 1.2    # Continued but slower improvement (increased from 0.8)
      std: 1.0
    year2:
      mean: 0.0    # Stable in year 2
      std: 1.0
    year3plus:
      mean: -0.3   # Slight decline after year 2
      std: 1.0

# Target outcomes for validation (from VIEW trials)
target_outcomes:
  year1:
    mean_bcva_change: 8.4        # Average of VIEW 1 (7.9) and VIEW 2 (8.9)
    vision_maintenance_rate: 0.954  # 95.4% average
    gainers_15_plus_rate: 0.310    # 31.0% average
    mean_injections: 7.5
  year2:
    mean_injections: 11.2        # Cumulative by week 96

# Calibration notes
# Version 2.0 improvements from Version 1.0:
# 1. Increased naive_treated mean from 3.0 to 4.5 (+50%)
# 2. Increased stable_treated mean from 1.5 to 2.5 (+67%)
# 3. Increased active_treated mean from 0.5 to 1.5 (+200%)
# 4. Changed highly_active_treated from -0.5 to +0.5 (now positive)
# 5. Increased NAIVE->STABLE transition from 45% to 55%
# 6. Increased ACTIVE->STABLE transition from 35% to 45%
# 7. Increased treatment multiplier for ACTIVE->STABLE from 2.5x to 3.0x
# 8. Increased good responder multiplier from 2.0 to 2.5
# 9. Increased average responder multiplier from 1.2 to 1.5
# 10. Increased loading phase mean from 3.5 to 5.0
# 11. Increased year1 mean from 0.8 to 1.2